Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Artelo Biosciences, Inc. (ARTL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.70, with a market capitalisation of $2.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.45 to $179.19. This page covers its latest market performance, valuation, price trends and company information.
$2.67M | |
$5.53 | |
$351,280.80 | |
$4.45 | |
$5.34 | |
89.96K | |
52.29K | |
-- | |
$179.19 | |
$4.45 | |
-- | |
-- |
Artelo Biosciences, Inc. (ARTL) is trading at $4.70 in pre-market trading as of 2026-09-16 12:17:00, down 11.99% ($0.64) from the previous close of $5.34
Pre-market trading shows how investors are pricing ARTL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Artelo Biosciences, Inc. (ARTL) moved from $6.04 to $4.70, representing a decline of 22.19% ($1.34).
The stock traded between $4.45 and $6.41 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 42.82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.1%
ARTL is currently trading at $4.70, placing it 0.1% of the way from its 52-week low of $4.45 to its 52-week high of $179.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Artelo Biosciences, Inc. (ARTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.